Skip Nav Destination
Issues
October 2024
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
ISSN 2235-1795
EISSN 1664-5553
In this Issue
Liver Cancer 2024, Vol. 13, No. 5
Editorial
Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Liver Cancer (2024) 13 (5): 459–467.
https://doi.org/10.1159/000540801
Guidelines
Management Consensus Guidelines for Hepatocellular Carcinoma: 2023 Update on Surveillance, Diagnosis, Systemic Treatment, and Posttreatment Monitoring by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
Wei Teng; Hung-Wei Wang; Shi-Ming Lin; On behalf of Diagnosis Group and Systemic Therapy Group of TLCA
Liver Cancer (2024) 13 (5): 468–486.
https://doi.org/10.1159/000537686
Research Article
Combination Assay of Methylated HOXA1 with Tumor Markers Shows High Sensitivity for Detection of Early-Stage Hepatocellular Carcinoma
Yuki Kunimune; Yutaka Suehiro; Issei Saeki; Yurika Yamauchi; Norikazu Tanabe; Toshihiko Matsumoto; Shingo Higaki; Ikuei Fujii; Chieko Suzuki; Naoko Okayama; Mitsuaki Nishioka; Kiyoshi Ichihara; Hiroaki Nagano; Isao Sakaida; Taro Takami; Takahiro Yamasaki
Liver Cancer (2024) 13 (5): 487–497.
https://doi.org/10.1159/000536211
Prognostic Value of Pathological Response for Patients with Unresectable Hepatocellular Carcinoma Undergoing Conversion Surgery
Zhen-Xin Zeng; Jia-Yi Wu; Jun-Yi Wu; Zhi-Bo Zhang; Kai Wang; Shao-Wu Zhuang; Bin Li; Jian-Yin Zhou; Zhong-Tai Lin; Shu-Qun Li; Yi-Nan Li; Yang-Kai Fu; Mao-Lin Yan
Liver Cancer (2024) 13 (5): 498–508.
https://doi.org/10.1159/000536376
Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma– with Emphasis on Locoregional Therapy for Oligoprogression
Tsung-Hao Liu; San-Chi Chen; Kun-Ming Rau; Li-Chun Lu; Po-Ting Lin; Yung-Yeh Su; Wei Teng; Shiue-Wei Lai; Ren-Hua Yeh; Tsui-Mai Kao; Pei-Chang Lee; Chi-Jung Wu; Chien-Hung Chen; Chih-Hung Hsu; Shi-Ming Lin; Yi-Hsiang Huang; Li-Tzong Chen; Ann-Lii Cheng; Ying-Chun Shen; on behalf of Taiwan Liver Cancer Association Research Group (TRG)
Liver Cancer (2024) 13 (5): 509–521.
https://doi.org/10.1159/000536549
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study
Federico Rossari; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Changhoon Yoo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Francesca Bergamo; Elisabeth Amadeo; Francesco Vitiello; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Massimo Iavarone; Giuseppe Cabibbo; Margarida Montes; Francesco Giuseppe Foschi; Caterina Vivaldi; Caterina Soldà; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Hiraoka; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Mara Persano; Silvia Foti; Silvia Camera; Bernardo Stefanini; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini; Margherita Rimini
Liver Cancer (2024) 13 (5): 522–536.
https://doi.org/10.1159/000537915
Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT
Richard S. Finn; Shukui Qin; Fabio Piscaglia; Thomas R. Jeffry Evans; Jennifer J. Knox; Carlos López López; Zahra Ramji; Min Ren; Kalgi Mody; Arndt Vogel; Masatoshi Kudo
Liver Cancer (2024) 13 (5): 537–547.
https://doi.org/10.1159/000537947
Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study
Richard S. Finn; Masatoshi Kudo; Gisoo Barnes; Tim Meyer; Frederic Boisserie; Ramil Abdrashitov; Yaxi Chen; Songzi Li; Andrew X. Zhu; Shukui Qin; Arndt Vogel
Liver Cancer (2024) 13 (5): 548–560.
https://doi.org/10.1159/000537966
Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
Byeong Geun Song; Aryoung Kim; Myung Ji Goh; Wonseok Kang; Geum-Youn Gwak; Yong-Han Paik; Moon Seok Choi; Joon Hyeok Lee; Dong Hyun Sinn
Liver Cancer (2024) 13 (5): 561–571.
https://doi.org/10.1159/000538301
